Diabetes Care, Vol 23, Issue 12 1823-1829, Copyright © 2000 by American Diabetes Association

ARTICLES

Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial

P O'Hare, R Bilbous, T Mitchell, CJ O' Callaghan and GC Viberti
Sir Quentin Hazel Institute of Molecular Medicine, University of Warwick, Gibbet Hill, Coventry, CV47AL, England, U.K.

OBJECTIVE: To assess if low (1.25 mg) and/or standard (5 mg) doses of the ACE inhibitor ramipril could prevent progression of microalbuminuria (incipient diabetic nephropathy) in normotensive type 1 diabetic patients. RESEARCH DESIGN AND METHODS: This study, using a multicenter randomized placebo-controlled double-blind parallel group, was conducted over 2 years in 28 outpatient diabetic clinics in the U.K. and Ireland. We screened 334 type 1 diabetic patients with suspected microalbuminuria and normal blood pressure; of these, 140 patients 18-65 years of age with a diagnosis of type 1 diabetes and persistent microalbuminuria, defined as urinary albumin excretion rate (AER) of 20-200 microg/min, were enrolled in the study. RESULTS: The proportion of patients progressing to macroalbuminuria was reduced in the ramipril groups but did not reach statistical significance over 2 years. AER was significantly lower at year 2 in the combined ramipril-treated patients versus placebo (P = 0.013). More patients on ramipril regressed to normoalbuminuria (<20 microg/min), with 11% for 1.25 mg ramipril, 20% for 5 mg ramipril, and 4% for placebo (P = 0.053). Blood pressure was significantly reduced to a similar extent with both 1.25 and 5 mg ramipril. Supine systolic blood pressure increased from 130 to 134 mmHg in the placebo group and fell in the 1.25 mg ramipril group (from 132 to 129 mmHg) and in the 5 mg ramipril group (from 134 to 130 mmHg) (P = 0.003, compared with placebo). No statistically significant changes were observed in glomerular filtration rate (GFR) between the placebo- and ramipril-treated groups during the 2-year period. CONCLUSIONS: Microalbuminuria is reduced significantly by ramipril treatment in type 1 diabetic patients without hypertension. Although the magnitude of the response was greater, there is no significant difference between responses to 1.25 or 5 mg ramipril. Small but highly significant reductions in systolic and mean arterial pressures occur in ramipril-treated patients. GFR is stable at this stage of the evolution of diabetic nephropathy and is unaffected by ramipril treatment for 2 years.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Buleon, J. Allard, A. Jaafar, F. Praddaude, Z. Dickson, M.-T. Ranera, C. Pecher, J.-P. Girolami, and I. Tack Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1249 - F1256. [Abstract] [Full Text] [PDF]

				L. Weekers, B. Bouhanick, S. Hadjadj, Y. Gallois, R. Roussel, F. Pean, A. Ankotche, G. Chatellier, F. Alhenc-Gelas, P. J. Lefebvre, et al. Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients Diabetes, October 1, 2005; 54(10): 2961 - 2967. [Abstract] [Full Text] [PDF]

				A. B. Rosen, M. B. Hamel, M. C. Weinstein, D. M. Cutler, A. M. Fendrick, and S. Vijan Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes Ann Intern Med, July 19, 2005; 143(2): 89 - 99. [Abstract] [Full Text] [PDF]

				M. Ravera, E. Ratto, S. Vettoretti, D. Parodi, and G. Deferrari Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S48 - S52. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				I. S. Harris, I. Treskov, M. W. Rowley, S. Heximer, K. Kaltenbronn, B. N. Finck, R. W. Gross, D. P. Kelly, K. J. Blumer, and A. J. Muslin G-Protein Signaling Participates in the Development of Diabetic Cardiomyopathy Diabetes, December 1, 2004; 53(12): 3082 - 3090. [Abstract] [Full Text] [PDF]

				M. Marre, M. Lievre, G. Chatellier, J. F E Mann, P. Passa, and J. Menard Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ, February 28, 2004; 328(7438): 495. [Abstract] [Full Text] [PDF]

				N. K. Hollenberg Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy: What Do We Know, and What Do We Need to Learn? Arch Intern Med, January 26, 2004; 164(2): 125 - 130. [Full Text] [PDF]

				L. Poulsen Review: Early renal involvement in Type 1 diabetes mellitus -- Part 2: ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 17 - 26. [Abstract] [PDF]

				A. D Vuong and L. G Annis Ramipril for the Prevention and Treatment of Cardiovascular Disease Ann. Pharmacother., March 1, 2003; 37(3): 412 - 419. [Abstract] [Full Text] [PDF]

				F. Enseleit, T.F. Luscher, and F. Ruschitzka Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A31 - A36. [Abstract] [PDF]

				G. Deferrari, M. Ravera, L. Deferrari, S. Vettoretti, E. Ratto, and D. Parodi Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S224 - 229. [Abstract] [Full Text]

				P. Swales and B. Williams Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 79 - 89. [Abstract] [PDF]

				H.-H. Parving, N. Chaturvedi, G. Viberti, and C. E. Mogensen Does Microalbuminuria Predict Diabetic Nephropathy? Diabetes Care, February 1, 2002; 25(2): 406 - 407. [Full Text]

				B. Fabris, R. Candido, M. Carraro, F. Fior, M. Artero, C. Zennaro, M. R. Cattin, A. Fiorotto, M. Bortoletto, C. Millevoi, et al. Modulation of Incipient Glomerular Lesions in Experimental Diabetic Nephropathy by Hypotensive and Subhypotensive Dosages of an ACE Inhibitor Diabetes, November 1, 2001; 50(11): 2619 - 2624. [Abstract] [Full Text] [PDF]